We think that the blood flow increases during intraarterial injection of a special drug, called iloprost, during surgical treatment in the distal limbs, because of the vasodilatation in diabetics and non diabetics in the same way.

The intraoperative arterial measurement of the blood flow after Iloproststimulation in diabetics and non-diabetics: Implication for Outcome - prediction and perioperative therapy. - ILOFLOW1.0

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-004567-80-AT

Enrollment

Registered

2012-04-18

Start date

2012-06-05

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way because of vasodilatation. So we investigate people with arteriosclerosis and diabetes and non diabetes which undergo surgical treatment.

Interventions

Trade Name: Ilomedin Product Name: Ilomedin Product Code: 1-22460 Pharmaceutical Form: Concentrate and solvent for injection INN or Proposed INN: Iloprost CAS Number: 78919-13-8 Current Sponsor code:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients between 18-99 years, women, men, patients with diabetes and non-diabetes, patients with arteriosclerosis and who undergo surgical treatment in distal vessels Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 30 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30

Exclusion criteria

Exclusion criteria: pregnancy, heart attack, stroke in the last 6 months, hypotension, edema of the lungs, heart failure, heart diseases, COPD, ulcus ventriculi, renal diseases, coronary diseases, immaturity

Design outcomes

Secondary

Measure	Time frame
Secondary end point(s): We don`t think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way.;Timepoint(s) of evaluation of this end point: 2 years	—

Primary

Measure	Time frame
Main Objective: We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way because of vasodilatation. ;Secondary Objective: We don`t think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way.;Primary end point(s): We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way.;Timepoint(s) of evaluation of this end point: 2 years	—

Measure

Time frame

Main Objective: We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way because of vasodilatation. ;Secondary Objective: We don`t think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way.;Primary end point(s): We think that the blood flow increases during intraarterial injection of iloprost during surgical treatment in distal vessels in patients with arteriosclerosis and diabetes and non diabetes in the same way.;Timepoint(s) of evaluation of this end point: 2 years

—

Countries

Austria

Contacts

Public ContactDr. Kornelia Hirsch

Wilhelminenspital, Abteilung für Chirurgie mit Schwerpunkt Gefässchirurgie, vasculäre und endovasculäre Chirurgie

kornelia.hirsch@wienkav.at0043(0)1491504101

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026